Abstract
Germline genetic testing affords multiple opportunities for women with breast cancer relating to (i) treatment of a current breast cancer, (ii) management of risk of future cancers, and (iii) identification of at-risk family members. In the UK, testing remains restricted to individuals at highest a-priori risk of carrying a pathogenic variant (<20% of women diagnosed with a breast cancer). The main barrier to expanding testing is a shortage of clinical resource due to current requirements to complete complex eligibility assessments, 1:1 pre-test genetic counselling, and pathway management.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
